Trial Profile

Total lymphoid irradiation and anti-thymocyte globulin as conditioning for non-myeloablative allogeneic hematopoietic cell transplantation for the treatment of myelodysplastic syndromes and myeloproliferative disorders (except CML [chronic myeloid leukemia]).

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antithymocyte globulin (Primary)
Indications Graft-versus-host disease; Haematological disorders; Myelodysplastic syndromes
Focus Adverse reactions; Therapeutic Use

18 Mar 2015 Biomarkers information updated
11 Feb 2011 Planned end date changed from 1 Dec 2012 to 1 Jul 2017 as reported by ClinicalTrials.gov.
01 Apr 2009 Planned end date added to 1 Dec 2012 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com